Gilead Sciences Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 decreased by 63.6% to $4.00M in Q1 2026 compared to the prior quarter.
A shift toward this bucket suggests a strategy focused on locking in longer-term yields.
This represents the amortized cost of debt securities in the available-for-sale portfolio that have maturity dates betwe...
Standard maturity bucket reporting for insurance investment portfolios.
other_available_for_sale_securities_debt_maturities_afte_0f7586| Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $15.00M | $7.00M | $14.00M | $17.00M | $6.00M | $7.00M | $11.00M | $4.00M |
| QoQ Change | — | -53.3% | +100.0% | +21.4% | -64.7% | +16.7% | +57.1% | -63.6% |
| YoY Change | — | — | — | +13.3% | -14.3% | — | — | — |